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Abstract 
Background: Klebsiella pneumoniae is a Gram‑negative bacterial species well known for its capacity to cause infec‑
tions in humans, and to carry and spread a wide variety of resistance genes including extended‑spectrum beta‑lac‑
tamase genes, carbapenem resistance genes, and colistin resistance genes. Recently, our real‑time laboratory‑based 
surveillance system MARSS (the Marseille Antibiotic Resistance Surveillance System) allowed us to observe a intring‑
ing dramatic decrease in the beta‑lactam resistance level of the K. pneumoniae strains routinely isolated from patients 
hospitalized in our settings since 2013. Here we study the evolution of the prevalence of K. pneumoniae infections in 
Marseille university hospitals, France, from January 2012 to July 2015, and study their antibiotic resistance profiles.
Methods: We collected data referring to patients hostpitalized for K. pneumoniae infections in the 4 university hospi‑
tals of Marseille from January 2012 to July 2015. We then study their antibiotic resistance profiles according the clinical 
sites from which each strain was collected. Antibiotic consumption data from our four hospitals were also analyzed 
from January 2013 to July 2015.
Results: Overall, 4868 patients were admitted in our settings for K. pneumoniae infections over the study period. 
Overall, 40.1, 22.3, 25.6, 0.4, 29.9, 14.8, 27.3 and 37.0 % of the strains were resistant to amoxicillin plus clavulanic acid, 
piperacillin‑tazobactam, ceftriaxone, imipenem, ciprofloxacin, gentamicin, trimethoprim‑sulfamethoxazole and furan, 
respectively. 447 were invasive infections. The resistance level of our invasive strains was significantly lower than that 
presented by 11, 7, 10 and 11 other European countries included in the 2013 European Antimicrobial Resistance 
Surveillance Network report for ceftriaxone, imipenem, ciprofloxacin and gentamicin, respectively, but significantly 
higher than that of 13, 1, 17 and 13 European countries for the same antibiotics. We also observed that the percent‑
ages of resistance of our invasive strains to three of the four antibiotics decreased over the study. In parallel, antibiotic 
consumption remained stable in our four hospitals from January 2013 to July 2015.
Conclusions: Altogether, our results underline that automated antibiotic‑susceptibility testing results‑based surveil‑
lance systems are crucial to better understand the evolving epidemiology of dangerous pathogenic bacterial species, 
like K. pneumoniae, at local scales.
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Background
Klebsiella pneumoniae is a non-motile, rod-shaped, 
Gram-negative bacterium naturally present in the envi-
ronment but equally in humans, where it can colonize 
the nasopharynx, the skin, but equally the gastrointesti-
nal tract (Berrazeg et  al. 2013; Ramos et  al. 2014). This 
bacterial species is well known worldwide for its capac-
ity to cause infections in humans (mostly blood stream, 
urinary and respiratory tract infections), especially in 
hospitalized patients with impaired immune systems like 
diabetics and newborns (European Centre for Disease 
Prevention and Control 2013). Because of its capacity to 
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survive on the skin and to spread rapidly in the hospital 
environment, it can be responsible for large nosocomial 
outbreaks transferred via the hands of hospital personnel 
(Ramos et al. 2014; European Centre for Disease Preven-
tion and Control 2013).
Similar to other Enterobacteriaceae, K. pneumoniae 
has extraordinary capacities for carrying and spreading 
a wide variety of resistance genes including extended-
spectrum beta-lactamase genes like SHV, CTX and 
AmpC (Harris et al. 2015), carbapenem resistance genes 
including NDM, KPC, IMP and VIM (Rolain et al. 2010; 
Nordmann and Carrer 2010), and more recently colistin 
resistance genes, especially mgrB, pmrA, pmrB, phoP and 
phoQ genes (Olaitan et al. 2014). Infections with multid-
rug-resistant K. pneumoniae represent real public health 
challenges. Numerous studies have shown that these 
infections increase the mortality, the cost of treatment 
and the hospital stays of infected patients (Schwaber and 
Carmeli 2007; Daroukh et al. 2014).
In order to detect and quickly fight possible hospital 
outbreaks due to multidrug-resistant bacterial strains 
belonging to 15 bacterial species of clinical interest 
(Escherichia coli, Klebsiella pneumoniae, Proteus mira-
bilis, Enterobacter cloacae, Klebsiella oxytoca, Enterobac-
ter aerogenes, Morganella morganii, Serratia marcescens, 
Pseudomonas aeruginosa, Acinetobacter baumannii, 
Streptococcus agalactiae, Enterococcus faecalis, Ente-
rococcus faecium, Staphylococcus aureus and Staphylo-
coccus epidermidis), we decided in 2013 to implement, 
based on data routinely produced by the four university 
hospitals of Marseille, our own real-time laboratory-
based surveillance system, MARSS (the Marseille Anti-
biotic Resistance Surveillance System) (Abat et al. 2015). 
This surveillance system allowed us to observe a dramatic 
decrease in the beta-lactam resistance level of the K. 
pneumoniae strains routinely isolated from patients hos-
pitalized in our settings since 2013.
Here we present and study the level of resistance 
to antibiotics of K. pneumoniae strains isolated from 
patients admitted in our settings between January 2012 
and July 2015. We then compare our results with avail-
able data.
Methods
All the data studied herein were retrospectively collected 
from the laboratory management system of the four uni-
versity hospitals of Marseille. These hospitals included 
the North (approximately 600 beds), South (900 beds), 
Conception (700 beds) and Timone (1500 beds) hospi-
tals. The collected data were raw data on antibiotic sus-
ceptibility testing routinely performed on K. pneumoniae 
strains isolated from hospitalized patients between Jan-
uary 2012 and July 2015. All the K. pneumoniae strains 
included in the study were identified using Matrix 
Assisted Laser Desorption Ionisation—Time of Flight 
(MALDI-TOF) mass spectrometers according to the 
MALDI-TOF identification score previously defined and 
published by our laboratory (i.e. identification score ≥1.9 
for good species identification) (Seng et  al. 2013, 2009). 
K. pneumoniae mass spectrometry spectra currently pre-
sent in our spectra database are presented in Additional 
file 1: Table S1.
Once collected, the data were processed in a Microsoft 
Excel database, and duplicates were removed to conserve 
single bacteria-patient couples to ensure the good quality 
of the analysis performed here. The infections were clas-
sified according to the sample from which each K. pneu-




















Fig. 1 Main samples infected by our 4868 K. pneumoniae strains, January 2012–July 2015
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Extracted data included antibiotic results for amoxicillin 
plus clavulanic acid, piperacillin-tazobactam, ceftriaxone, 
imipenem, ciprofloxacin, gentamicin, trimethoprim-
sulfamethoxazole and furan. In our laboratory, antibiotic 
susceptibility testing is performed following the EUCAST 
recommendations. Therefore, all were obtained perform-
ing disk diffusion tests. Moreover, E tests of imipenem 
are routinely performed to validate or not possible imi-
penem-resistant K. pneumoniae resistance phenotypes. 
Percentages of resistance to ceftriaxone, imipenem, cipro-
floxacin and gentamicin of our invasive strains (meaning 
our K. pneumoniae strains responsible for bacteremia or 
meningitis) were compared to those available in the 2013 
European Antimicrobial Resistance Surveillance Network 
(EARS-Net) report (European Centre for Disease Preven-
tion and Control 2013). These data only included one bac-
teremia or meningitis record per patient infected by the 
bacterium at the community or hospital level classified 
per country included in the EARS-Net report. In order 
to determine the part of invasive K. pneumoniae infec-
tions that were hospital-acquired infections, we classified 
them according to the delay between the date of sampling 
and the date of hospitalization of each patient included in 
this study. Thus, hospital-acquired invasive K. pneumo-
niae infections were defined as infections that occurred at 
least 3 days after the hospitalization of the patient in our 
settings.
Antimicrobial consumption data from our four hos-
pitals for Ceftriaxone, Ciprofloxacin, Gentamicin and 
Imipenem were extracted then sorted per hospital in 
Microsoft Excel sheets. Only data from January 2013 to 
July 2015 were analyzed (data for 2012 were not available 
for analysis).
Statistical analyses were performed using the R soft-
ware (Auckland, New-Zealand). We performed two-
sided Pearson’s Chi Square tests. p values <0.05 were 
considered statistically significant.
As our K. pneumoniae strains were collected from 
patients in France during standard hospital procedures, 
no written consent was needed, in accordance with the 
‘LOI no. 2004-800 relative à la bioéthique’ published in 
the Journal Officiel de la République Française, 6 August 
2004.
Results
4868 non-redundant patients were admitted in our set-
tings for K. pneumoniae infections from January 2012 to 
July 2015, especially for urinary-tract infections (3360 
infections, 69 % of the overall number of K. pneumoniae 
infections studied here) (Fig.  1). Overall, the number of 
K. pneumoniae infections remained stable over the years 
and the hospitals (Table  1). In parallel, antibiotic con-
sumption for Ceftriaxone, Ciprofloxacin, Gentamicin 
and Imipenem remained stable in our four hospitals from 
January 2013 to July 2015 (Additional file 2: Table S2).
Globally, 40.1, 22.3, 25.6, 0.4, 29.9, 14.8, 27.3 and 37.0 % 
of the strains were resistant to amoxicillin plus clavulanic 
acid, piperacillin-tazobactam, ceftriaxone, imipenem, 
ciprofloxacin, gentamicin, trimethoprim-sulfamethoxa-
zole and furan, respectively. The annual evolution of the 
percentage of resistance of all our K. pneumoniae strains 
to ceftriaxone, imipenem, ciprofloxacin and gentamicin 
is presented Fig.  2. Overall, these percentages of resist-
ance did not statistically change except for imipenem, 
for which the resistance level of our strains significantly 
increased from 2012 to 2015 (p value: 0.02).
The comparison of the resistance level of our K. 
pneumoniae strains isolated from invasive infections 
with those presented by the other European countries 
included in the EARS-Net report is shown in Table  2. 
Overall, 447 invasive K. pneumoniae infections occurred 
over the study period in our settings, with a non-sig-
nificant increase in the number of invasive infections 
between 2012 and 2013 (p value = 0.9, Table 1). 45 % of 
Table 1 Distribution of our 4868 K. pneumoniae strains per kind of infection, hospitals and years
a K. pneumoniae infections not classifiable among the different hospitals
b Two-sided Pearson’s Chi Square test performed comparing the total number of K. pneumoniae infections identified in 2012 and 2013 to the number of K. 
pneumoniae invasive infections observed the same years. p value of <0.05 was considered statistically significant
c From January 2015 to July 2015



















2012 362 29 285 397 102 1175 32 0 31 44 8 115 0.9
2013 409 48 353 405 86 1301 44 1 29 47 9 130
2014 404 35 342 363 134 1278 42 2 41 39 11 135
2015c 207 24 170 112 154 667 22 1 17 9 18 67
Total 1382 136 1150 1277 476 4421 140 4 118 139 46 447
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these infections (203 infections) were hospital-acquired 
infections. We observed that the level of resistance of 
our invasive strains was significantly lower than that pre-
sented by 11, 7, 10 and 11 other European countries for 
ceftriaxone, imipenem, ciprofloxacin and gentamicin, 
respectively (Table  2). On the other hand, the level of 
resistance of our invasive strains was significantly higher 
than that of 13, 1, 17 and 13 European countries for the 
same antibiotics (Table  2). Figure  3 shows the annual 
evolution of the percentage of resistance of our invasive 
K. pneumoniae strains to ceftriaxone, imipenem, cipro-
floxacin and gentamicin. We observed that the percent-
ages of resistance of our invasive K. pneumoniae strains 
to three of the four antibiotics decreased from January 
2012 to July 2015 (0.7, 0.6 and 0.9-fold decrease for ceftri-
axone, ciprofloxacin and gentamicin, respectively). How-
ever, none of these decreases were statistically significant 
between 2012 and 2015.
Discussion
K. pneumoniae is an important pathogen that can carry 
and spread various resistance genes in the community 
and at the hospital level. Indeed, from 1980 to 2000, K. 
pneumoniae strains were found to carry and disperse 
various resistance genes worldwide, especially through 
nosocomial infections, including TEM, SHV and CTX-M 
type extended-spectrum beta-lactamase, and AmpC 
cephalosporinase (Molton et  al. 2013). They were also 
involved in the global spread of carbapenemase encoding 
genes, including KPC enzymes (Munoz-Price et al. 2013).
Our results allowed us to observe that the K. pneu-
moniae strains responsible for invasive infections in our 
hospitals from January 2012 to July 2015 were signifi-
cantly more resistant to antibiotics (excluding imipenem) 
than most of those responsible for invasive infections 
in the other European countries included in the 2013 
EARS-Net report (European Centre for Disease Preven-
tion and Control 2013) (Table 2). However, interestingly, 
our results also allowed us to identify that over the 
study period, the annual resistance level of our invasive 
K. pneumoniae strains to the four antibiotics of interest 
globally decreased (Fig.  3). This is surprising, especially 
when the 2013 EARS-Net report observed the opposite 
trends since 2010 in most of the European countries, 
including France (European Centre for Disease Preven-
tion and Control 2013). These observations could be 
explained by local successive emergence-replacement 
events of more or less resistant K. pneumoniae clones 
expressing genes making them particularly adapted to 
our environment. A similar phenomenon was observed 
and described by Ramos et  al. in 2014. Indeed, after 
analyzing the genomic content of a specific Klebsiella 
pneumoniae carbapenemase (KPC)-2-producing K. 
pneumoniae clone called Kp 13 responsible for a large 
nosocomial outbreak in a teaching hospital located in 
the south of Brazil (Ramos et al. 2014), the authors con-
cluded that the genes harbored by this K. pneumoniae 
clone might explain its ability to rapidly spread at the 
hospital level.
The peak of antibiotic resistance especially observed 
in invasive K. pneumoniae strains isolated in 2013 in our 
hospitals (Fig.  3) can be explained by successive oxacil-
linase-48 carbapenemase–producing K. pneumoniae real 
nosocomial outbreaks identified by MARSS involving 
patients especially hospitalized in our intensive care units 
the same year (Abat et  al. 2015). Although we continue 
to isolate few OXA-48 producing K. pneumoniae strains, 
the measures taken in our hospitals to fight this threat 
led to the dramatic decrease in the number of isolation 
of OXA-48 producing K. pneumoniae strains, which can 
possibly explain the lower antibiotic resistance level of 
the K. pneumoniae strains isolated from 2014 to 2015 in 
our settings (Figs. 2, 3).
Our results finally underlined that only a few num-
bers of all our K. pneumoniae strains (20 strains, 0.4 %) 
were resistant to imipenem (Table  2; Fig.  3). This is 
good news considering the fact that our region is closed 
to Italy and Greece, two countries where KPC-produc-
ing K. pneumoniae strains have become endemic since 
2008 and 2007, respectively (Munoz-Price et al. 2013). 
Moreover, a recent study observed that molecules clas-
sified as ‘old antibiotics’ present good in  vitro activity 
against highly resistant Gram-negative bacteria, includ-
ing imipenem-resistant K. pneumoniae (Dubourg et al. 
2015).
The fact that we did not perform a further genomic 
analysis of local K. pneumoniae strains responsible for 
invasive infections represents a major limitation of our 
study. We believe that such analyses should be performed 
in the future to better characterize the specific K. pneu-

















Fig. 2 Annual resistance level of our 4868 K. pneumoniae strains, 
January 2012–July 2015
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limitation consists in the fact that our definition of hospi-
tal-acquired infections did not take into account the pos-
sible movements of patients between different hospitals, 
which can introduce bias in our calculations of the num-
ber of hospital and/or community-acquired infections.
In conclusion, our results allowed us to conclude that 
automated laboratory-based surveillance systems imple-
mented for the monitoring of antibiotic-susceptibility 
testing results of K. pneumoniae strains isolated from 
hospitalized patients are crucial to quickly identify resist-
ant clone outbreaks (Abat et  al. 2015), but equally to 
better understand the evolving epidemiology of this dan-
gerous pathogenic bacterial species at local scales.
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Fig. 3 Annual resistance level of our 447 invasive K. pneumoniae 
strains, January 2012–July 2015
